Anders Fugelli, Chief Executive Officer, Ph.D
+47 924 81 432
A pharmaceutical company developing drugs for neurological and autoimmune/metabolic diseases.
Pharmasum Therapeutics is a private Norwegian pharmaceutical company focused on the discovery and development of novel drugs for treatment of neurological and autoimmune/metabolic diseases with a significant unmet medical need.
Pharmasum Therapeutics´ development candidate PST-674 is a potent DYRK1A protein kinase for treatment of dementia in Down syndrome – a clinical indication where current therapy options are lacking.
The Company expects that the results from the DYRK1A development program will be transferrable to treating other dementias such as dementia in Parkinson’s Disease and Dementia with Lewy Bodies as well as Alzheimer´s disease in the general population.
Pharmasum has offices in Oslo Science Park, Norway, and holds an international team with extensive R&D expertise based in Norway, UK and US.